Finanzen von Mesa Laboratories Inc (MLAB)MLABMesa Laboratories Inc

Mesa Laboratories, Inc. (MLAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Discrete Revenues- Consumables, accounting for 62.9% of total sales, equivalent to $40.06M. Other significant revenue streams include Discrete Revenues- Hardware and Software and Contracted Revenues- Services. Understanding this composition is critical for investors evaluating how MLAB navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Mesa Laboratories, Inc. maintains a gross margin of 64.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 11.69%, while the net margin is 4.71%. These profitability ratios, combined with a Return on Equity (ROE) of 2.66%, provide a clear picture of how effectively MLAB converts its operational activities into shareholder value.

In the context of the broader market, MLAB competes directly with industry leaders such as CTKB and MDXG. With a market capitalization of $705.97M, it holds a leading position in the sector. When comparing efficiency, MLAB's gross margin of 64.87% stands against CTKB's 58.87% and MDXG's 68.50%. Such benchmarking helps identify whether Mesa Laboratories, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 66.23% in Q4 2026, showing improvement in profitability despite recent earnings volatility. However, net income was negative in Q4 2026, reflecting ongoing challenges.